MD, FRCP(C)
Professor of Psychiatry and Pharmacology,
University of Toronto
Head, Mood Disorders Psychopharmacology Unit,
University Health Network
Program Clinical Director, Mental Health and Addictions,
The Royal Victoria Regional Health Centre
Toronto, ON
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto. Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022 and 2023 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has authored/co-authored more than 1100 peer-reviewed articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada. Additionally, Dr. McIntyre was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Research Foundation in 2023.
Dr. McIntyre has also contributed extensively to clinical practice guidelines. For example, Dr. McIntyre is the lead author of the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. In addition, Dr. McIntyre is also the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders as well as the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
MD, FRCPC
Professor, Department of Psychiatry and Behavioural Neurosciences,
McMaster University
Hamilton, ON
Dr. Michael Van Ameringen is a Professor in the Department of Psychiatry and Behavioural Neurosciences at McMaster University. His current research is focused on the psychopharmacology of Anxiety and Mood Disorders, Obsessive-Compulsive and Related Disorders, ADHD, treatment resistance and the use of psychedelics and GLP-1 receptor agonists in psychiatric disorders. Other research interests include the use of medical cannabis for anxiety and related disorders and problematic Internet use.
He is the Anxiety Lead for The Canadian Network for Mood and Anxiety Treatments (CANMAT). He is the lead author in the 2025 CANMAT-ICOCS International Guidelines for the treatment of OCD. He was also a member of the Steering Committee for the Canadian Anxiety Disorder Treatment Guidelines, and the World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders; and a co-author of the 2023 CANMAT Depression guidelines. He recently co-authored the CANMAT Task Force Report on Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Dr. Van Ameringen is Co-Chair of the Obsessive-Compulsive Research Network of the European College of Neuropsychopharmacology (ECNP), and a member of the Scientific Council of the Anxiety and Depression Association of America. He is the Associate Editor for the International Journal of Psychiatry in Clinical Practice and is on the editorial board for the Journal of Mood and Anxiety, Journal of Psychiatric Research and Comprehensive Psychiatry.
He is also an associate faculty member of the Michael G. DeGroote Centre for Medicinal Cannabis Research and is the Director of the ADHD Fellowship Program in the Department of Psychiatry and Behavioural Neurosciences at McMaster University. Dr. Van Ameringen has published widely in the area of OCD, ADHD and Anxiety Disorders.
MD, PhD
Chair in Evidence-Based Mental Health, Director of Research,
Psychiatry Department, University of Ottawa
Medical Director, The Ottawa Hospital
Scientist, Charite' University, Berlin
Marco Solmi is a psychiatrist and the Clinical Research Chair in Evidence-Based Mental Health. He is Associate Professor and Director of Research, at the Department of Psychiatry of University of Ottawa. He is also the Medical Director of the On Track First Episode Psychosis program and of the Eating Disorders program at The Ottawa Hospital.
He is a scientist at the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the Charité University Medicine in Berlin, and a visiting academic at University of Southampton, School of psychology in the UK.
He is Chair of ECNP Physical And meNtal Health (PAN-Health) Network, member of the board of directors of the Canadian consortium for Early Intervention in Psychosis, and member of the other European and Canadian psychiatric associations. He is interested in meta-research and epidemiology to study prevention/early interventions, psychopharmacology, and physical health in those with mental disorders.
He authored over 550 publications in leading medical journals and is cited over 50,000 times.
MD, FRCPC, CCFP, MPH, BSc
Clinical Associate Professor, University of Calgary
Section Chief for Addictions, Rural Psychiatry, Claresholm Centre for Mental Health and Addictions
Calgary, Alberta
Dr. Tim Ayas is a Clinical Associate Professor with the University of Calgary Department of Psychiatry. He has a number of educational and administrative roles as well as a busy clinical practice; but his passion is teaching students, residents, psychiatrists, family physicians, and multidisciplinary teams across Canada and internationally.
He serves on the executive board for the Department of Psychiatry as the Section Chief responsible for Addictions, Rural Psychiatry at the Claresholm Centre for Mental Health and Addictions. He recently stepped down as Clerkship Director of Psychiatry at the University of Calgary Cumming School of Medicine.
He primarily works at the Claresholm Centre and Edgewood Health Networks as a psychiatrist with a focus on addictions and concurrent disorders. He has provided expert consultation for a number of organizations including Calgary City Hall, Global Television, CTV, CBC National Radio, and the House of Commons.
He has won numerous teaching awards including the 2021 Canadian Organization of Undergraduate Psychiatric Educators COUPE national teaching award recognized at the annual Canadian Psychiatric Association Scientific Conference.
MD, CM, MSc, FRCPC
Director, PEPP-MUHC (program for the evaluation and prevention of psychosis)
Director, Schizophrenia program, MUHC
Associate Professor, Department of Psychiatry, McGill University
Dr. Margolese is an Associate Professor in the Department of Psychiatry of McGill University. He is currently the program director of the McGill Clinical Pharmacology and Toxicology residency program. He is director of the PEPP first episode psychosis and Schizophrenia programs at the McGill University Health Centre and director of the Clinical Psychopharmacology and Therapeutics Unit.
He has given numerous lectures and presentations both nationally and internationally and has published over 75 articles. He is vice-president of research and a founding member of the Canadian Consortium for Early Intervention in Psychosis.
In his clinical work, Dr. Margolese specializes in psychopharmacology consultations, first episode psychosis, and treatment resistant schizophrenia.
Professor
Dr. Paul Janssen Chair in Psychotic Disorders
Director of Research, Department of Psychiatry, Dalhousie University
Clinical Director, Early Psychosis Intervention Nova Scotia
Nova Scotia Health
Dr. Tibbo received his B.Sc. (Hons) from Mount Alison University in Sackville, NB, and his MD from Memorial University of Newfoundland. He completed his residency in psychiatry at the University of Alberta and following this joined the staff at the University of Alberta Hospital as a clinician and researcher. He was instrumental in the development of and co-directed both the Bebensee Schizophrenia Research Unit and the Edmonton Early Psychosis Intervention Clinic.
In 2008 Dr. Tibbo was named the first Dr. Paul Janssen Chair in Psychotic Disorders, an endowed research chair, at Dalhousie University in Halifax NS. He is a Professor in the Department of Psychiatry with a cross-appointment in Psychology and Neuroscience at Dalhousie University. He is Director of Research for the Department of Psychiatry at Dalhousie and Clinical Director of the provincial Early Psychosis Intervention Nova Scotia (EPINS) program for Nova Scotia Health. Dr Tibbo is President of the Canadian Consortium for Early Intervention in Psychosis (CCEIP), helping to advance early intervention care at the national level.
Dr. Tibbo’s publications are primarily in the area of schizophrenia with his current foci of study including individuals at the early phase of, and at risk for, a psychotic illness. Dr. Tibbo’s areas of research include application of in vivo brain neuroimaging techniques to study psychosis as well as research interests in co-morbidities in schizophrenia (primarily substance misuse and psychosis), pathways to care/service delivery, education, and non-pharmacological treatment options. He is funded by local and national peer reviewed funding agencies and well published in leading journals. Dr Tibbo was a recipient of the Canadian Alliance on Mental Illness and Mental Health’s Champion of Mental Health Research award in 2017 and the 2018 Royal College of Physicians and Surgeons of Canada Prix d’Excellence - Specialist of the Year (region 5).
Dr. Atul Khullar is a psychiatrist and sleep specialist who focuses on the integrative management of obesity, sleep, mood/anxiety and attention deficit disorders in age groups from adolescence onwards. Recently, he has gained expertise in the selective use of ketamine for resistant mood disorders.
He completed his medical school and residency at the University of Alberta, and a sleep and mood/anxiety disorders fellowship at the University of Toronto. He has additional pediatric sleep medicine training from the University of Pennsylvania.
Dr. Khullar is board-certified in Psychiatry and Sleep Medicine in both Canada and the United States. He is also a fellow of the American Academy of Sleep Medicine, Diplomate of the American Board of Obesity Medicine, and a Clinical Associate Professor at the University of Alberta.
Actively involved in research and education, Dr. Khullar has given more than 600 invited presentations to public and professional audiences worldwide. He has published a number of articles and chapters as well as chaired more than 20 national CME programs in his specialized areas.
Currently, he is the medical director of the Northern Alberta Sleep Clinic in Edmonton. Dr. Khullar is also a senior consultant for the Grey Nuns Hospital, the Edmonton Oilers, the Newly Institute and MedSleep, a Canada-wide network of community sleep clinics. He has also worked with the Canadian Winter Olympic team in the past.
Professor of Neurology, Department of Clinical Neurological Sciences
Western University, London, Ontario
Received MD from Western University, where I also did training in Internal Medicine and Neurology, receiving my fellowship in Neurology from the Royal College of Physicians and Surgeons of Canada.
I did a Medical Research Council of Canada sponsored research fellowship with Professor Joseph Martin at Harvard Medical School and the Massachusetts General Hospital in Boston and then returned to Western University in London Ontario.
Professor of Neurology in the Department of Clinical Neurological Sciences.
After doing General Neurology with a special interest in Neuroendocrinology for 39 years, I now limit my practice to headache Neurology.
MBBS, FRCPC
Director, UBC Headache Clinic
Associate Clinical Professor, Neurology
University of British Columbia
Dr. Spacey is a Neurologist and Clinical Associate Professor in the Division of Neurology at UBC. She completed a residency in Neurology at UBC and a fellowship in Neurogenetics at Queen Square, London England. She is Director of the UBC Headache Clinic and UBC Neurogenetics Clinic. She is past president of the Canadian Headache Society and Director of the UBC Clinician Investigator Program. She lectures nationally and internationally. Her research interest and publications are in the field of calcium channels and the pathogenesis and molecular genetics of migraine.
BSc MSc MD FRCPC, Pain Psychiatrist
Clinical Assistant Professor, University of British Columbia
Director, UBC Pain Medicine Residency Program
Dr. Michael Butterfield is a Clinical Assistant Professor at UBC with appointments in the Departments of Psychiatry and Anesthesiology, Pharmacology & Therapeutics. He has a keen interest in medical education and has been the Director of the UBC Pain Medicine Residency Program for 5 years. He practices clinically at various tertiary pain clinics and the UBC Headache Clinic. He is a member of several national committees in the areas of pain medicine and psychiatry and was recently awarded the Early Career Achievement in Psychiatry Award by the Canadian Psychiatric Association.
Message